Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy.
Supachaya SriphoosanaphanKessarin ThanapiromSirinporn SuksawatamnuayPanarat ThaimaiSukanya SittisomwongKanokwan SonsiriNunthiya SrisoonthornNicha TeeratornNattaporn TanpowpongBundit ChaopathomkulSombat TreeprasertsukYong PoovorawanPiyawat KomolmitPublished in: BMC gastroenterology (2020)
Curative treatment with DAA attenuated the liver stiffness and inflammation but did not improve VD levels. Over 80% of patients remained VD insufficient/deficient. Whether VD replacement during and after DAA therapy can improve hepatic fibrosis remains unclear. Trial registration The Thai Clinical Trial Registry as TCTR20161025001 (31 October 2016). http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=2136 .
Keyphrases
- clinical trial
- end stage renal disease
- prognostic factors
- ejection fraction
- study protocol
- phase ii
- sars cov
- chronic kidney disease
- phase iii
- peritoneal dialysis
- randomized controlled trial
- patient reported outcomes
- stem cells
- helicobacter pylori
- mesenchymal stem cells
- bone marrow
- replacement therapy
- double blind
- combination therapy
- liver fibrosis